2023
Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer
Cartmel B, Li F, Zhou Y, Gottlieb L, Lu L, Mszar R, Harrigan M, Ligibel J, Gogoi R, Schwartz P, Risch H, Irwin M. Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer. Cancer Medicine 2023, 12: 15492-15503. PMID: 37269192, PMCID: PMC10417064, DOI: 10.1002/cam4.6187.Peer-Reviewed Original ResearchConceptsExercise interventionOvarian cancerTrial of exerciseExercise-induced changesMin/weekGroup differencesSubset of participantsCause mortalityExercise groupOverall survivalStudy armsCA 125Randomized trialsBlood biomarkersBlood drawBreast cancerClinical significanceIGF-1Effect model analysisSecondary analysisBeneficial effectsCancerBiomarkersTrialsWomenA review of the impact of energy balance on triple-negative breast cancer
Akingbesote N, Owusu D, Liu R, Cartmel B, Ferrucci L, Zupa M, Lustberg M, Sanft T, Blenman K, Irwin M, Perry R. A review of the impact of energy balance on triple-negative breast cancer. JNCI Monographs 2023, 2023: 104-124. PMID: 37139977, DOI: 10.1093/jncimonographs/lgad011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTriple-negative breast cancerInterventional studyBreast cancerCancer treatmentClinical interventional studyClinical observationalImmune activationCancer outcomesCancer careClinical studiesOverall healthEnergy intakeNarrative reviewCancer cellsEnergy expenditureCancerTreatmentEnergy balanceOutcomesExerciseReviewDetrimental effectsImmunotherapyStudyIntakeA qualitative study identifying challenges resulting from complex evidence on lifestyle factors and cancer: perspectives from Black and Latina cancer survivors and healthcare providers
Pichardo M, Irwin M, Sanft T, Ferrucci L, Ginader A, Nguyen T, Esserman D, Cartmel B, Molina Y. A qualitative study identifying challenges resulting from complex evidence on lifestyle factors and cancer: perspectives from Black and Latina cancer survivors and healthcare providers. Supportive Care In Cancer 2023, 31: 111. PMID: 36633678, PMCID: PMC9912693, DOI: 10.1007/s00520-022-07539-9.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsOncology healthcare providersCancer survivorsLifestyle behaviorsHealthcare providersGeneric messagingEvidence-based knowledgeFemale breast cancer survivorsHealthcare provider counselingHealthy lifestyle guidelinesPatient-level barriersHealthy lifestyle behaviorsLifestyle guidelinesProvider counselingLifestyle factorsOncology careCancer outcomesBreast cancerConsistency of evidenceCurrent evidenceAvailable evidenceSurvivorsCancer diagnosisLevel barriersCancer
2022
Effect of exercise on body composition among women with ovarian cancer
Cao A, Cartmel B, Li FY, Gottlieb LT, Harrigan M, Ligibel JA, Gogoi R, Schwartz PE, Irwin ML, Ferrucci LM. Effect of exercise on body composition among women with ovarian cancer. Journal Of Cancer Survivorship 2022, 17: 1386-1396. PMID: 35377104, PMCID: PMC9530065, DOI: 10.1007/s11764-022-01207-x.Peer-Reviewed Original ResearchConceptsDual-energy X-ray absorptiometryOvarian cancer survivorsAerobic exercise interventionEffects of exerciseCancer survivorsOvarian cancerExercise interventionBody compositionSix-month aerobic exercise interventionBone mineral densityBetween-group differencesBody fat percentageLean body massX-ray absorptiometrySecondary outcomesStudy armsAerobic exerciseLifestyle StudyMineral densityHigh riskCancerSurvivorsFat percentageWomenResultsOn average
2012
The burden of cancer in Connecticut.
Gonsalves L, Cartmel B, Mueller L. The burden of cancer in Connecticut. Connecticut Medicine 2012, 76: 335-51. PMID: 22856019.Peer-Reviewed Original Research
2009
Epidemiology and Intervention Trials
Mayne S, Wright M, Cartmel B. Epidemiology and Intervention Trials. Carotenoids 2009, 191-210. DOI: 10.1007/978-3-7643-7501-0_10.ChaptersChronic diseasesDeterminants of diseaseIntervention trialsHeart diseaseCarotenoid statusMacular degenerationCarotenoid intakeDisease endpointsEpidemiological researchDiseaseOxidative stressHealth effectsAntioxidant functionEpidemiologyRiskEtiologyCancerCataractDegenerationHuman populationIntakeTrialsEndpoint
2001
Predictors for cutaneous basal‐ and squamous‐cell carcinoma among actinically damaged adults
Foote J, Harris R, Giuliano A, Roe D, Moon T, Cartmel B, Alberts D. Predictors for cutaneous basal‐ and squamous‐cell carcinoma among actinically damaged adults. International Journal Of Cancer 2001, 95: 7-11. PMID: 11241303, PMCID: PMC2637530, DOI: 10.1002/1097-0215(20010120)95:1<7::aid-ijc1001>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaSkin cancerRisk factorsNon-melanoma skin cancerSCC incidence ratesAge 61 yearsRed hair colorGroup of menActinic lesionsBCC occurrencePlacebo groupChemoprevention trialsCutaneous basalBCC lesionsMale genderIncidence ratePrior historySun damageSubstantial incidenceOlder ageCancerFirst SCCExposure factorsAdult residenceCarcinoma
1997
Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group.
Moon T, Levine N, Cartmel B, Bangert J, Rodney S, Dong Q, Peng Y, Alberts D. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiology Biomarkers & Prevention 1997, 6: 949-56. PMID: 9367069.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaNew squamous-cell carcinomasModerate-risk subjectsSkin cancerHazard ratioNew nonmelanoma skin cancersSquamous cell skin cancerIU of retinolNew skin cancersPlacebo-supplemented subjectsPrimary end pointNonmelanoma skin cancerFree-living subjectsEffect of retinolMedian followOral retinolBasal cell carcinoma skin cancersActinic keratosesRetinol supplementationCell carcinomaDaily supplementationAdverse symptomsEnd pointCancerNew BCCTrial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group.
Levine N, Moon T, Cartmel B, Bangert J, Rodney S, Dong Q, Peng Y, Alberts D. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiology Biomarkers & Prevention 1997, 6: 957-61. PMID: 9367070.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaSquamous cell carcinomaBasal cell carcinomaNonmelanoma skin cancerCell carcinomaSkin cancerPlacebo-controlled trialHigh-risk subjectsSkin cancer preventionEffect of retinolOral retinolStudy clinicCancer preventionOutcome measuresIsotretinoinBeneficial effectsStudy periodRetinolTrialsCarcinomaCancerPreventionTotal numberParticipantsPlaceboRetinoids in prevention of skin cancer
Moon T, Levine N, Cartmel B, Bangert J. Retinoids in prevention of skin cancer. Cancer Letters 1997, 114: 203-205. PMID: 9103292, DOI: 10.1016/s0304-3835(97)04663-6.Peer-Reviewed Original ResearchConceptsBasal cell skin cancerModerate-risk subjectsPrior skin cancersHigh-risk subjectsRisk subjectsSkin cancerB trialSquamous cell skin cancerSquamous cell cancerEffects of retinoidsActinic keratosesCell cancerClinical trialsIntervention durationCancerTrialsRetinolRetinoidsPlaceboIncidencePreventionSubjectsSignificant benefitsIsotretinoinKeratoses